Not currently recruiting at UCSD
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
a study on Crohn's Disease Inflammatory Bowel Disease Immunotherapy
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at San Diego, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- ID
- NCT03345836
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated